Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + fluorouracil + filgrastim
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination chemotherapy regimen consisting of three cytotoxic agents (cyclophosphamide, doxorubicin, and fluorouracil) plus a supportive care medication (filgrastim). The FAC/CAF component is commonly used for breast cancer treatment, while filgrastim (G-CSF) is added to reduce the risk of neutropenia. Each component has a distinct mechanism of action: - Fluorouracil: An antimetabolite that stops cells from making and repairing DNA - Doxorubicin: An anthracycline that inhibits DNA production and interferes with DNA repair enzymes - Cyclophosphamide: An alkylating agent that prevents cancer cell reproduction - Filgrastim: A granulocyte colony-stimulating factor that stimulates the bone marrow to produce neutrophils
- Other names
- FAC + filgrastimCAF + filgrastim
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + fluorouracil + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + fluorouracil + filgrastim.